Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$138.10

-0.58 (-0.42%)

, ITCI

Intra-Cellular

$16.83

-0.38 (-2.21%)

12:25
10/23/18
10/23
12:25
10/23/18
12:25

JPMorgan pharma and biotech analysts to hold analyst/industry conference call

Smid Cap Biotech Analyst Fye, U.S. Major & Specialty Pharma Analyst Schott and Large Cap Biotech Analyst Kasiamov, along with Key Opinion Leader Dr. Aaronson, Clinical Research Director at the Sheppard Pratt Health System discuss the treatment landscape for biopolar depression and depressive disorders on an Analyst/Industry conference call to be held on October 23 at 1 pm.

JNJ

Johnson & Johnson

$138.10

-0.58 (-0.42%)

ITCI

Intra-Cellular

$16.83

-0.38 (-2.21%)

AGN

Allergan

$185.90

-1.85 (-0.99%)

SAGE

Sage Therapeutics

$118.28

0.25 (0.21%)

ALKS

Alkermes

$39.00

0.14 (0.36%)

ACAD

Acadia

$21.76

-0.01 (-0.05%)

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 19

    Dec

  • 31

    Jan

JNJ Johnson & Johnson
$138.10

-0.58 (-0.42%)

10/17/18
WELS
10/17/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson price target raised to $160 from $155 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Johnson & Johnson to $160 from $155 following quarterly results. The analyst reiterates an Outperform rating on the shares.
10/16/18
PIPR
10/16/18
NO CHANGE
PIPR
Piper Jaffray discusses derivatives from J&J's Q3 results
Piper Jaffray analyst Matt O'Brien notes that Johnson & Johnson's (JNJ) global Medical Devices segment grew 1.7% organically in Q3, with sales of $6.6B falling $50M short of the consensus. The large joint segment continues to look relatively stable, with low-single-digit pricing pressures as expected, O'Brien tells investors in a research note. The analyst suspects Stryker (SYK) will continue to take share away from J&J and Zimmer Biomet (ZBH) in Q3. J&J's Spine segment was flat off of easy comps and after normalizing the Codman divestiture, the analyst adds. He continues to view J&J as a "share donor" to the pure-play spine names Globus Medical (GMED), NuVasive (NUVA) and SeaSpine (SPNE), with Globus' robot "continuing to provide share taking opportunities." Within Contact Lenses, J&J faced tough comps but reported a solid quarter in both the domestic and international markets, O'Brien says. He continues to see a "healthy" lens end market and one that is shifting to daily lenses from reusable, which he views as positive for Cooper Companies (COO). Further, the analyst notes that Diabetes continues to decelerate for J&J at a negative 20% clip given the Animas exit, which he thinks continues to be a positive for the pump names Insulet (PODD) and Tandem Diabetes (TNDM).
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Gilead may need Dicerna after Arrowhead, J&J deal, says Citi
Given the partnership announced yesterday between Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ), Gilead Sciences' (GILD) hepatitis B virus portfolio may need another component and Dicerna Pharmaceuticals (DRNA) "could be one of them," Citi analyst Robyn Karnauskas tells investors in a research note. The analyst believes large pharma and Gilead are "still missing a key piece to bring a curative therapy to market that can rapidly and effectively lower HBsAg." The Arrowhead deal makes it apparent that HBV portfolios may need a multi-target approach and validates the RNAi platform to target HBV, the analyst contends.
ITCI Intra-Cellular
$16.83

-0.38 (-2.21%)

04/03/18
LEER
04/03/18
NO CHANGE
Target $25
LEER
Outperform
Intra-Cellular selloff on Alkermes news 'unwarranted,' says Leerink
Leerink analyst Geoffrey Porges notes that Alkermes (ALKS) announced a Refusal to File Letter from the FDA for ALKS-5461. ALKS-5461 is often linked with Intra-Cellular's (ITCI) lumateperone since both drugs are seeking approval in major psychiatric indications, and the analyst believes investors are considering the ALKS-5461 outcome as a proxy for the FDA's flexibility about approving lumateperone in 2019. However, Porges believes the "sympathy" selloff in Intra-Cellular, based on the Alkermes news, is "unwarranted" for several reasons, and does not believe the RTF letter for ALKS-5461 impacts the likelihood of the FDA's acceptance of the lumateperone NDA later this year, or lumateperone's approval in 2019. He reiterates an Outperform rating and $25 price target on Intra-Cellular's shares.
08/23/18
CANT
08/23/18
NO CHANGE
Target $32
CANT
Overweight
Intra-Cellular transferred with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan took over coverage of Intra-Cellular Therapies with an Overweight rating and $32 price target. The analyst sees a high probability of approval for lumateperone in schizophrenia.
04/02/18
CANT
04/02/18
NO CHANGE
Target $28
CANT
Overweight
Intra-Cellular weakness on ALKS 5642 news 'unsurprising,' says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner reiterates an Overweight rating and $28 price target on Intra-Cellular (ITCI), but acknowledges that ALKS 5641-related weakness is "unsurprising" as Alkerme's (ALKS) drug and lumateperone "have been joined, somewhat, at the hip." The analyst believes lumateperone is not just about Schizophrenia and could be an important treatment for several neuropsychological disorders. Further, Tanner views the PDE-1 enzyme inhibitor ITI-214 as being an attractive drug candidate with potential to expand Intra-Cellular's footprint into other neurological disorders for which large unmet medical needs exist.
04/03/18
ADAM
04/03/18
NO CHANGE
Target $31
ADAM
Buy
Intra-Cellular weakness a buying opportunity, says Canaccord
Canaccord analyst Sumant Kulkarni noted Intra-Cellular (ITCI) sold off on the news the FDA issued a Refusal to File letter on Alkermes (ALKS) for its major depressive disorder drug candidate. The analyst views the pullback in Intra-Cellular as a buying opportunity heading into the mid-2018 potential filing of its own lumateperone drug for depression, as it is a more conventional design. Kulkarni reiterated his Buy rating and $31 price target on Intra-Cellular shares.
AGN Allergan
$185.90

-1.85 (-0.99%)

10/16/18
JMPS
10/16/18
NO CHANGE
Target $34
JMPS
Outperform
Aclaris Therapeutics price target lowered to $34 from $47 at JMP Securities
JMP Securities analyst Donald Ellis lowered his price target on Aclaris Therapeutics (ACRS) shares to $34 from $47 after the company announced a deal to acquire Rhofade from Allergan (AGN) and disclosed unaudited Q3 Eskata sales of about $0.5M, which missed his prior estimate of $2.8M. His lower price target is attributable to his updated Eskata estimates with the launch proceeding slower than expected, but Ellis maintains an Outperform rating on Aclaris shares, stating that he sees the Rhofade deal as "strategic and accretive."
10/18/18
WELS
10/18/18
NO CHANGE
WELS
Outperform
Allergan migraine update 'very positive' news, says Wells Fargo
Allergan yesterday announced the completion of two positive safety and tolerability studies for its oral anti-CGRP acute migraine treatment, ubrogepant, Wells Fargo analyst David Maris tells investors in a research note titled ": Effective? Check. Safe? Check. Oral Migraine Drug Clears Key Hurdle." The data showcase what Allergan has reiterated all along, that ubrogepant has shown to provide triptan-like efficacy in treating acute migraines with a lower adverse event profile and an absence of drug-induced elevated liver enzyme levels, Maris contends. The analyst, who currently models $175M in sales for ubrogepant in 2022, believes many on the Street are underestimating Allergan and ubrogepant "given the past concerns over hepatic safety that do not appear to be evident." Ubrogepant may have $1B-plus sales potential if approved, says Maris. He finds yesterday's safety update as "very positive" news for Allergan and keeps an Outperform rating on the stock.
10/18/18
MZHO
10/18/18
NO CHANGE
Target $210
MZHO
Buy
Allergan reported clean safety profile for migraine treatment, says Mizuho
Allergan yesterday reported a clean safety profile in two safety studies of ubrogepant for the treatment of acute migraine, Mizuho analyst Irina Koffler tells investors in a research note. The analyst believes these results may also de-risk atogepant, Allergan's second follow-on oral CGRP program in migraine prophylaxis. She reiterates a Buy rating on the shares with a $210 price target.
10/16/18
JEFF
10/16/18
NO CHANGE
Target $33
JEFF
Buy
Jefferies boosts Aclaris target to $33 on expected Rhofade accreation
Jefferies analyst David Steinberg raised his price target for Aclaris Therapeutics (ACRS) to $33 from $30 after the company acquired Rhofade from Allergan (AGN). As Allergan has already done much of the "heavy lifting" for the launch, and the product leverages Aclaris' current sales force, Rhofade should be accretive to EBITDA in Q4 of 2019, Steinberg tells investors in a research note. The analyst believes the drug is potentially a best in class product for skin condition rosacea. He thinks peak sales could conservatively reach $60M and keeps a Buy rating on Aclaris Therapeutics.
SAGE Sage Therapeutics
$118.28

0.25 (0.21%)

10/17/18
STFL
10/17/18
NO CHANGE
Target $239
STFL
Buy
Stifel confident in approval of Sage Therapeutics' brexanolone ahead of AdComm
Ahead of an FDA advisory committee meeting on Nov 2 to review brexanolone, Stifel analyst Paul Matteis said he is confident in FDA approval and expects the debate on the drug to be centered on labeling, REMS and necessary monitoring requirements. While noting that brexanolone comprises a minority of his Sage valuation, Matteis said the most important thing for the stock is that the panel is both positive and doesn't raise any sort of issue that would read negatively onto SAGE-217, which comprises the majority of his Sage valuation. He maintains a Buy rating and $239 price target on Sage Therapeutics shares.
08/07/18
PIPR
08/07/18
NO CHANGE
Target $206
PIPR
Overweight
Sage Therapeutics continues to make progress on Zulresso, says Piper Jaffray
Sage Therapeutics continues to make progress preparing for potential FDA approval/launch of Zulresso for post partum depression, Piper Jaffray analyst Danielle Brill tells investors in a research note following the company's Q2 results. The analyst expects the FDA panel on November 2 to be supportive of approval. She reiterates an Overweight rating on Sage shares with a $206 price target.
10/10/18
OPCO
10/10/18
INITIATION
Target $170
OPCO
Outperform
Sage Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson started Sage Therapeutics with an Outperform rating and $170 price target. Sage should become a leader in anti-depressants with two drugs in late-stage development, IV brexanolone for postpartum depression and oral SAGE-217 for postpartum depression and major depressive disorder, Olson tells investors in a research note titled "Thyme to Buy SAGE." He believes the company's near-term catalysts are "skewed toward positive outcomes" and "could unlock significant value."
10/11/18
10/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sage Therapeutics (SAGE) initiated with an Outperform at Oppenheimer. 2. Herbalife Nutrition (HLF) initiated with a Buy at Jefferies. 3. GreenSky (GSKY) initiated with a Buy at BTIG. 4. Nightstar Therapeutics (NITE) initiated with an Overweight at Cantor Fitzgerald. 5. KLX Energy (KLXE) initiated with a Buy at Gabelli. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ALKS Alkermes
$39.00

0.14 (0.36%)

08/13/18
JEFF
08/13/18
NO CHANGE
Target $49
JEFF
Hold
Psychiatrists believe ALKS 3831 needs 50% treatment effect, says Jefferies
Jefferies analyst Biren Amin polled 25 psychiatrists who treat adult schizophrenia about Alkermes' ALKS 3831 and the upcoming Q4 readout for the Phase III Enlighten-2 trial evaluating the drug to olanzapine in patients with schizophrenia. Clinicians believe a 50% reduction in weight gain at six months would be clinically meaningful, but that this "may be a high bar," Amin tells investors in a research note. If Enlighten-2 shows less than a 50% reduction, price may play a key consideration in its adoption, the analyst adds. He currently models ALKS 3831 at peak sales of $500M. Amin has a Hold rating on Alkermes with a $49 price target.
08/06/18
STFL
08/06/18
INITIATION
STFL
Hold
Alkermes initiated with a Hold at Stifel
08/07/18
STFL
08/07/18
INITIATION
Target $45
STFL
Hold
Alkermes initiated with a Hold at Stifel
Stifel analyst Paul Matteis initiated coverage of Alkermes with a Hold rating and a $45 price target, stating that he has a more positive than consensus view on Aristada for schizophrenia and BIIB098 for Multiple Sclerosis, but a more cautious view on Vivitrol for addiction. While he is "cautiously optimistic" on ALKS3831 data in schizophrenia due in the fourth quarter, he is pessimistic on the odds of FDA approval for ALKS5461 for treatment-resistant depression without another positive clinical study, Matteis tells investors.
09/21/18
SBSH
09/21/18
NO CHANGE
SBSH
Buy
Alkermes risk/reward favorable into FDA panel meeting, says Citi
Citi analyst Liav Abraham believes expectations heading into November's FDA panel on Alkermes' depression drug are low, implying a favorable risk-reward heading into the event. While key opinion leaders have expressed concerns around ALKS 5461's "mixed" clinical data, they acknowledge the need for alternative therapeutic options in the adjunctive major depressive disorder space given, Abraham tells investors in a research note. The analyst sees reasons for the panel to vote either way ahead of the release of the briefing documents. She keeps a Buy rating on Alkermes.
ACAD Acadia
$21.76

-0.01 (-0.05%)

10/16/18
CANT
10/16/18
NO CHANGE
Target $27
CANT
Overweight
Acadia price target raised to $27 from $25 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Acadia Pharmaceuticals to $27 and reiterates an Overweight rating on the shares. Acadia in August announced a licensing agreement with Neuren Pharmaceuticals for Trofinetide in Rett syndrome, Duncan tells investors in a research note. The analyst believes this is an underappreciated asset that could diversify the company's pipeline strategy over the next 12 months. After meeting with Neuren, Duncan has enhanced conviction on Trofinetide and believes that the path forward increases Phase 3 probability of success in the "as-yet untreatable neurodevelopmental disorder."
10/08/18
PIPR
10/08/18
NO CHANGE
Target $25
PIPR
Overweight
Piper a buyer of Acadia ahead of Nuplazid depression data
After reviewing available data for other agents that act as 5HT2AR antagonists, Piper Jaffray analyst Danielle Brill is "incrementally more optimistic" that Acadia Pharmaceuticals' Nuplazid will at least demonstrate a trend of efficacy in the ongoing Phase 2 Clarity trial in major depressive disorder. The current share price around $21 reflects only the base business in Parkinson's disease psychosis, Brill tells investors in a research note. She adds that her $25 price target for Acadia shares does not include any value for major depressive disorder. As such, the analyst believes downside is "likely marginal" on the Phase 2 data while upside could be anywhere from 30%-45%. Brill is a buyer of Acadia ahead of the data and reiterates an Overweight rating on the shares with a $25 price target.
09/21/18
09/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss saying he views the stock's risk/reward as more balanced following the recent underperformance. 2. Acadia (ACAD) upgraded to Overweight from Neutral at Piper Jaffray with analyst Danielle Brill citing the FDA announcement of maintained support for Nuplazid after its review. 3. AT&T (T) upgraded to Buy from Neutral at UBS with analyst John Hodulik saying the stock is trading near all-time low valuations, and at its widest valuation gap to Verizon (VZ), given a mix of EBITDA declines, concerns over the debt load and secular issues impacting the space. 4. Diamond Offshore (DO) upgraded to Buy from Hold at HSBC. 5. Ingersoll-Rand (IR) upgraded to Overweight from Neutral at JPMorgan with analyst Stephen Tusa saying he views the stock's discounted valuation relative to peers as unwarranted following the company's transformation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/18
HCWC
09/21/18
NO CHANGE
Target $60
HCWC
Buy
Acadia shares should normalize after FDA safety clearance, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein said the FDA announcement of its conclusion that no new or unexpected safety risks associated with Nuplazid were identified eliminates the worse case scenario for Acadia and he believes the stock should normalize following the FDA safety clearance. He expects a gradual reversal of the negative impact on sales that had been prompted by the CNN report and sees additional indications having the potential to "markedly expand" Nuplazid's commercial upside. Fein reiterates a Buy rating and $60 price target on Acadia shares.

TODAY'S FREE FLY STORIES

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:23
11/16/18
11/16
18:23
11/16/18
18:23
Periodicals
CPUC isn't ruling out board shuffle, breakup for PG&E, Bloomberg says »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.04

0.05 (0.38%)

18:00
11/16/18
11/16
18:00
11/16/18
18:00
Periodicals
Barrick Gold looking to add more copper, bullion assets, Reuters reports »

Barrick Gold is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$33.05

0.165 (0.50%)

17:57
11/16/18
11/16
17:57
11/16/18
17:57
Hot Stocks
Aqua America CEO acquires over 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

, XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

17:39
11/16/18
11/16
17:39
11/16/18
17:39
General news
Week ending ETF scorecard: Real Estate leads, Consumer Discretionary slumps »

S&P500 SECTORS: Real…

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

XLU

Utilities SPDR

$54.86

0.77 (1.42%)

XLI

Industrial Select Sector SPDR

$72.00

(0.00%)

XLV

Health Care Select Sector SPDR

$92.05

0.91 (1.00%)

XLF

Financial Select Sector

$26.78

0.03 (0.11%)

XLP

Consumer Staples Sector SPDR

$56.04

0.15 (0.27%)

XLE

Energy Select Sector SPDR

$67.23

0.76 (1.14%)

XLC

Communication Services Select Sector SPDR Fund

$44.88

-0.2 (-0.44%)

XLK

Technology Select Sector SPDR

$68.22

-0.1 (-0.15%)

XLY

Consumer Discretionary Sector SPDR

$106.37

-0.43 (-0.40%)

GLD

SPDR Gold Shares

$115.56

0.82 (0.71%)

SLV

iShares Silver Trust

$13.55

0.115 (0.86%)

USO

United States Oil Fund

$12.07

0.08 (0.67%)

UNG

United States Natural Gas Fund

$35.43

3.63 (11.42%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.24

-0.27 (-0.32%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$111.73

0.23 (0.21%)

TLT

iShares 20+ Year Treasury Bond Fund

$114.65

0.61 (0.53%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.13

0.3 (0.30%)

SHY

iShares 1-3 Year Treasury Bond

$83.13

0.08 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$17.02

0.23 (1.37%)

17:36
11/16/18
11/16
17:36
11/16/18
17:36
Hot Stocks
Aquestive receives CRL from FDA for tadalafil oral film »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

DAKT

Daktronics

$7.67

0.07 (0.92%)

17:35
11/16/18
11/16
17:35
11/16/18
17:35
Hot Stocks
Daktronics adopts new shareholder rights agreement »

Daktronics announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TI

Telecom Italia

$6.02

0.12 (2.03%)

17:33
11/16/18
11/16
17:33
11/16/18
17:33
Periodicals
Gubitosi viewed as frontrunner for Telecom Italia CEO job, Reuters says »

Veteran Italian manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAXR

Maxar Technologies

$18.77

-0.59 (-3.05%)

17:30
11/16/18
11/16
17:30
11/16/18
17:30
Hot Stocks
Maxar Technologies shareholders approve U.S. domestication »

Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.83

(0.00%)

17:28
11/16/18
11/16
17:28
11/16/18
17:28
Syndicate
Breaking Syndicate news story on Plug Power »

Plug Power files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSB

GlobalSCAPE

$4.55

-0.02 (-0.44%)

17:22
11/16/18
11/16
17:22
11/16/18
17:22
Syndicate
Breaking Syndicate news story on GlobalSCAPE »

GlobalSCAPE files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQIX

Equinix

$388.18

2.67 (0.69%)

17:19
11/16/18
11/16
17:19
11/16/18
17:19
Hot Stocks
Equinix's Lee sells 2,792 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

LMT

Lockheed Martin

$301.06

-4.42 (-1.45%)

17:17
11/16/18
11/16
17:17
11/16/18
17:17
Hot Stocks
Lockheed Martin awarded $282.09M Naval Sea Systems Command contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$2.56

0.045 (1.79%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Hot Stocks
Teligent receives notification of deficiency from Nasdaq »

Teligent said that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAF

Staffing 360 Solutions

$1.82

0.07 (4.00%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Syndicate
Breaking Syndicate news story on Staffing 360 Solutions »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

IMMR

Immersion

$9.56

-0.14 (-1.44%)

17:12
11/16/18
11/16
17:12
11/16/18
17:12
Hot Stocks
Breaking Hot Stocks news story on Immersion »

Man Group reports 4.84%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNX

Athenex

$11.95

0.74 (6.60%)

17:10
11/16/18
11/16
17:10
11/16/18
17:10
Hot Stocks
Breaking Hot Stocks news story on Athenex »

Perceptive Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 02

    Dec

TSRO

Tesaro

$34.96

8.39 (31.58%)

17:08
11/16/18
11/16
17:08
11/16/18
17:08
Recommendations
Tesaro analyst commentary at Piper Jaffray »

Piper Jaffray says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

EEI

Ecology & Environment

$10.50

-2 (-16.00%)

17:05
11/16/18
11/16
17:05
11/16/18
17:05
Hot Stocks
Ecology & Environment receives noncompliance notice from Nasdaq »

Ecology and Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEE

Ameren

$69.29

0.01 (0.01%)

16:58
11/16/18
11/16
16:58
11/16/18
16:58
Hot Stocks
Ameren exec Nelson sells $690,000 worth of common shares »

Ameren SVP, general…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQS

Equus II Inc

$1.86

(0.00%)

16:56
11/16/18
11/16
16:56
11/16/18
16:56
Hot Stocks
Equus II Inc reports net assets of $46.6M as of September 30 »

Equus Total Return…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAPO

Vapotherm

$17.10

-0.42 (-2.40%)

16:56
11/16/18
11/16
16:56
11/16/18
16:56
Hot Stocks
Breaking Hot Stocks news story on Vapotherm »

Redmile Group reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

COTY

Coty

$9.09

0.39 (4.48%)

16:55
11/16/18
11/16
16:55
11/16/18
16:55
Hot Stocks
Coty CEO acquires 2.3M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

NVS

Novartis

$87.74

0.52 (0.60%)

16:54
11/16/18
11/16
16:54
11/16/18
16:54
Upgrade
Novartis rating change at Goldman Sachs »

Novartis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

VIAB

Viacom

$33.00

1.13 (3.55%)

16:52
11/16/18
11/16
16:52
11/16/18
16:52
Syndicate
Breaking Syndicate news story on Viacom »

Viacom files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 04

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.